Sangamo Therapeutics' (SGMO) "Sector Perform" Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reaffirmed their sector perform rating on shares of Sangamo Therapeutics (NASDAQ:SGMO - Free Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $2.00 target price on the biopharmaceutical company's stock.

SGMO has been the topic of a number of other reports. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday, January 27th. StockNews.com lowered Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 24th. Jefferies Financial Group lowered their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating on the stock in a research note on Tuesday, December 31st. Wells Fargo & Company decreased their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating for the company in a research note on Tuesday, December 31st. Finally, Truist Financial lowered their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Sangamo Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $5.17.

Remove Ads

Sangamo Therapeutics Price Performance

SGMO stock traded up $0.03 during midday trading on Tuesday, hitting $0.87. The stock had a trading volume of 9,493,967 shares, compared to its average volume of 7,729,362. The company's 50-day moving average price is $1.07 and its 200 day moving average price is $1.41. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The firm has a market cap of $180.81 million, a PE ratio of -1.16 and a beta of 1.49.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $7.55 million during the quarter, compared to analyst estimates of $11.70 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. As a group, sell-side analysts anticipate that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. lifted its position in shares of Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company's stock worth $956,000 after purchasing an additional 57,125 shares in the last quarter. FMR LLC lifted its holdings in Sangamo Therapeutics by 16.5% in the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company's stock valued at $471,000 after buying an additional 77,032 shares during the period. State Street Corp lifted its holdings in Sangamo Therapeutics by 28.0% in the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company's stock valued at $576,000 after buying an additional 145,400 shares during the period. XTX Topco Ltd boosted its stake in Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company's stock valued at $90,000 after acquiring an additional 64,981 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Sangamo Therapeutics by 14.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company's stock valued at $1,853,000 after acquiring an additional 272,123 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.